Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.48 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 11/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16077808 | 0.92 | P2RX3 (0.49) | P2RX3UCHL1NR1H2NR1H3MCL1 | |
| SCHEMBL15984475 | 0.91 | P2RX3 (0.45) | P2RX3UCHL1NR1H2NR1H3MCL1 | |
| SCHEMBL15987117 | 0.90 | P2RX3 (0.48) | P2RX3UCHL1NR1H2NR1H3MCL1 | |
| SCHEMBL16077798 | 0.90 | P2RX3 (0.45) | P2RX3UCHL1NR1H2NR1H3PTPN1 | |
| SCHEMBL29991596 | 0.90 | P2RX3 (0.48) | P2RX3UCHL1NR1H2NR1H3MCL1 | |
| SCHEMBL14730353 | 0.90 | P2RX3 (0.48) | P2RX3UCHL1NR1H2NR1H3MCL1 | |
| SCHEMBL6864274 | 0.90 | P2RX3 (0.48) | P2RX3UCHL1NR1H2NR1H3MCL1 | |
| SCHEMBL19557118 | 0.87 | P2RX3 (0.43) | P2RX3UCHL1NR1H2NR1H3MCL1 | |
| SCHEMBL29991738 | 0.87 | P2RX3 (0.48) | P2RX3UCHL1NR1H2NR1H3MCL1 | |
| SCHEMBL8210282 | 0.86 | P2RX3 (0.46) | P2RX3UCHL1NR1H2NR1H3MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2015-09-24 | — | — | US | disclosed |
| EP-2459582-B1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-05-27 | — | — | EP | disclosed |
| US-8828930-B2 | Hepatitis C virus NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828930-B2 | Hepatitis C virus NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011014487-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | P2RX3 3516/4885UCHL1 483/4885NR1H2 1166/4885 |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, CTSC, GTF3C3 | P2RX3 3442/4885UCHL1 401/4885NR1H2 1209/4885 |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | P2RX3 3516/4885UCHL1 483/4885NR1H2 1166/4885 |
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | P2RX3 3494/4885UCHL1 579/4885NR1H2 703/4885 |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | RRP1B, ZC3HAV1, RNASE1 | P2RX3 3817/4885UCHL1 964/4885NR1H2 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.